Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors

本轮融资由 Nextech Invest 和 Norwest 联合领投，新老投资者均参与跟投

Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027

所得款项将用于支持MPT-062的临床开发，这是一款首创的口服T细胞调节剂，计划于2027年启动

WATERTOWN, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced the successful closing of a $150 million Series B financing. The financing was co-led by Nextech Invest and Norwest, with participation from new investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth.

马萨诸塞州沃特敦，2026年10月7日（环球社讯）——专注于精准共价药物发现的生物科技公司Matchpoint Therapeutics今日宣布成功完成1.5亿美元的B轮融资。本轮融资由Nextech Invest和Norwest联合领投，新投资者Invus、BB Biotech、T1D Fund和BOLD Longevity Growth参与投资。

Founding investors Access Biotechnology and Atlas Venture, lead Series A investor Sanofi Ventures, Digitalis Ventures, and all other existing investors also participated..

创始投资方 Access Biotechnology 和 Atlas Venture，A 轮领投方 Sanofi Ventures、Digitalis Ventures 以及所有其他现有投资者也参与了本轮投资。

In connection with the financing, Kanishka Pothula, Ph.D., Managing Partner at Nextech Invest, and Brian Matesic, M.D., Principal at Norwest, will join Matchpoint’s Board of Directors.

作为此次融资的一部分，Nextech Invest 的管理合伙人 Kanishka Pothula 博士和 Norwest 的原则投资人 Brian Matesic 博士将加入 Matchpoint 的董事会。

The proceeds from the financing will support progression of the lead asset, MPT-062, to clinical proof-of-concept and advancement of Matchpoint’s broader product pipeline. Matchpoint will also continue progressing an additional program funded by Novartis through their July 2025 agreement.

融资所得将用于支持核心资产 MPT-062 推进至临床概念验证阶段，并推动 Matchpoint 更广泛的产品管线的发展。Matchpoint 还将继续推进由诺华通过其 2025 年 7 月达成的协议资助的另一个项目。

“This Series B financing reflects our substantial progress in the discovery of differentiated first-in-class oral therapies for autoimmune and inflammatory diseases,” said Andre Turenne, Chief Executive Officer of Matchpoint. “We are deeply grateful to our new and existing investors for their support as we advance MPT-062 into clinical development and progress our other innovative programs.”.

“此次B轮融资反映了我们在发现针对自身免疫性和炎症性疾病的差异化首创口服疗法方面取得的重大进展，”Matchpoint首席执行官Andre Turenne表示。“在我们推进MPT-062进入临床开发并推动其他创新项目进展的过程中，我们深深感谢新老投资者的支持。”

Kanishka Pothula, Ph.D., commented, “MPT-062 could fundamentally change the management of many common immune-mediated inflammatory conditions with an oral medicine. Its first-in-class mechanism has the potential to precisely address the disease-causing overactivation of T cells. We’re proud to support Matchpoint’s bold pursuit of innovation in this space.”.

Kanishka Pothula 博士评论道：“MPT-062 有望通过一种口服药物，从根本上改变许多常见免疫介导性炎症性疾病的管理方式。其首创的作用机制具有精准针对导致疾病的 T 细胞过度激活的潜力。我们自豪地支持 Matchpoint 在这一领域大胆追求创新。”

“Matchpoint’s leading covalent drug discovery platform has made unprecedented advances against historically hard-to-drug targets,” added Brian Matesic, M.D. “We’re excited to support the company as it progresses its pipeline into the clinic and advances the development of truly differentiated medicines for patients with autoimmune diseases.”.

“Matchpoint 领先的共价药物发现平台在针对历来难以成药的靶点方面取得了前所未有的进展，”Brian Matesic 医学博士补充道。“我们很高兴支持该公司将其研发管线推进至临床阶段，并为自身免疫性疾病患者推动真正具有差异化优势的药物的开发。”

About Matchpoint Therapeutics

关于Matchpoint Therapeutics

Matchpoint Therapeutics is a privately held biotechnology company based in Watertown, Massachusetts, developing breakthrough oral medicines for autoimmune and inflammatory diseases. The company is pioneering a new generation of rationally designed covalent small molecules for biologically validated targets that have been historically hard to drug.

Matchpoint Therapeutics 是一家总部位于马萨诸塞州沃特敦的私营生物技术公司，致力于开发用于自身免疫性和炎症性疾病的突破性口服药物。该公司正在开创新一代合理设计的共价小分子药物，针对那些在生物学上已得到验证但历来难以进行药物开发的靶点。

Matchpoint’s discovery engine integrates deep expertise across chemical biology, covalent chemistry, structure-based drug design, and computational sciences. The company’s focused deployment of its platform has produced a pipeline of first-in-class programs and a discovery collaboration with Novartis..

Matchpoint 的发现引擎整合了化学生物学、共价化学、基于结构的药物设计以及计算科学领域的深厚专业知识。公司对其平台的专注部署已催生出一批首创类（first-in-class）研发项目，并与诺华（Novartis）建立了发现合作。

Matchpoint Media Contact:

Matchpoint 媒体联系人：

Cory Tromblee

科里·特伦布利

Scient PR

Scient 公关

Media@MatchpointTx.com

Media@MatchpointTx.com